No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Therapy Areas
Drug Classes
Therapy Areas
All Sessions
Resectable NSCLC
Advanced NSCLC
SCLC
Biomarkers
Drug Classes
Targeted Therapies
Immunotherapies
ADCs
All
FEATURED
ILCS
Webinars
Articles
Industry Sponsored
Featured Sessions
Expert Insights
Webinars
The Reading Room
Articles & Research
Sep
17
2026
INDUSTRY NEWS
Resectable NSCLCTargeted Therapies
Adjuvant osimertinib reduced the risk of death by 47% at eight years in ADAURA
Sep
15
2026
CONGRESS
Advanced NSCLCBiomarkersResectable NSCLC
WCLC 2026, day 4: tumour budding, BRAF class II and III, brain radiotherapy timing, and mobile CT screening
Sep
14
2026
CONGRESS
Resectable NSCLCTargeted Therapies
ADAURA at eight years: adjuvant osimertinib keeps a 15-point overall survival lead
Sep
14
2026
CONGRESS
Advanced NSCLCResectable NSCLCADCs
WCLC 2026, day 3: EGFR exon 20, ROS1 and HER2 in advanced NSCLC, and 79% alive at eight years after surgery
Sep
12
2026
CONGRESS
Advanced NSCLCResectable NSCLCSCLC
WCLC 2026, day 1: extended-interval and subcutaneous dosing in SCLC, and a 70% early response
Aug
31
2026
RESEARCH
Resectable NSCLCTargeted Therapies
Adjuvant alectinib held its advantage in ALINA’s Asia subgroup, on 31 events and immature survival data
H. Horinouchi
Aug
25
2026
RESEARCH
Resectable NSCLCTargeted Therapies
Fewer patients discontinued adjuvant alectinib than chemotherapy in ALINA, and quality-of-life gains held to two years
M. HochmairH. HorinouchiD. Planchard
Aug
19
2026
RESEARCH
BiomarkersResectable NSCLCImmunotherapies
AIOT expert panel endorses chemo-immunotherapy as a new standard in resectable stage II-III NSCLC
T. CasconeP. FordeA. Passaro
Aug
13
2026
RESEARCH
BiomarkersResectable NSCLCImmunotherapies
Pre-surgical ctDNA clearance reached 66% with neoadjuvant nivolumab against 38% with placebo in CheckMate 77T
T. Cascone
Aug
06
2026
RESEARCH
Resectable NSCLCTargeted Therapies
Adjuvant crizotinib did not prolong DFS in resected ALK-positive NSCLC
J. Sands
Aug
02
2026
RESEARCH
Resectable NSCLCImmunotherapies
Five-year event-free survival was 49.9% with perioperative pembrolizumab against 26.5% with chemotherapy alone in KEYNOTE-671
D. Rodríguez-AbreuM. Reck
Industry Sponsored
Featured Sessions
Expert Insights
Webinars
The Reading Room
Articles & Research
Sep
17
2026
INDUSTRY NEWS
Resectable NSCLCTargeted Therapies
Adjuvant osimertinib reduced the risk of death by 47% at eight years in ADAURA
Sep
15
2026
CONGRESS
Advanced NSCLCBiomarkersResectable NSCLC
WCLC 2026, day 4: tumour budding, BRAF class II and III, brain radiotherapy timing, and mobile CT screening
Sep
14
2026
CONGRESS
Resectable NSCLCTargeted Therapies
ADAURA at eight years: adjuvant osimertinib keeps a 15-point overall survival lead
Sep
14
2026
CONGRESS
Advanced NSCLCResectable NSCLCADCs
WCLC 2026, day 3: EGFR exon 20, ROS1 and HER2 in advanced NSCLC, and 79% alive at eight years after surgery
Sep
12
2026
CONGRESS
Advanced NSCLCResectable NSCLCSCLC
WCLC 2026, day 1: extended-interval and subcutaneous dosing in SCLC, and a 70% early response
Aug
31
2026
RESEARCH
Resectable NSCLCTargeted Therapies
Adjuvant alectinib held its advantage in ALINA’s Asia subgroup, on 31 events and immature survival data
H. Horinouchi
Aug
25
2026
RESEARCH
Resectable NSCLCTargeted Therapies
Fewer patients discontinued adjuvant alectinib than chemotherapy in ALINA, and quality-of-life gains held to two years
M. HochmairH. HorinouchiD. Planchard
Aug
19
2026
RESEARCH
BiomarkersResectable NSCLCImmunotherapies
AIOT expert panel endorses chemo-immunotherapy as a new standard in resectable stage II-III NSCLC
T. CasconeP. FordeA. Passaro
Aug
13
2026
RESEARCH
BiomarkersResectable NSCLCImmunotherapies
Pre-surgical ctDNA clearance reached 66% with neoadjuvant nivolumab against 38% with placebo in CheckMate 77T
T. Cascone
Aug
06
2026
RESEARCH
Resectable NSCLCTargeted Therapies
Adjuvant crizotinib did not prolong DFS in resected ALK-positive NSCLC
J. Sands
Aug
02
2026
RESEARCH
Resectable NSCLCImmunotherapies
Five-year event-free survival was 49.9% with perioperative pembrolizumab against 26.5% with chemotherapy alone in KEYNOTE-671
D. Rodríguez-AbreuM. Reck